

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6877

Title: Clinical management of advanced gastric cancer: the role of new molecular drugs

Reviewer code: 02446379

Science editor: Su-Xin Gou

Date sent for review: 2013-10-30 14:56

Date reviewed: 2013-12-05 21:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The authors presented in this interesting paper the role of new molecular drugs in advanced gastric cancer. Using all databases available De Vita Ferdinando et al. have provided a comprehensive literature review regarding the above mentioned issue. They have managed to show that new ways of treatment should be taken into account when we face a patient with advanced gastric or gastro-esophageal junction cancer. Especially, when the first line treatment has failed. Overall the paper is well written and the language is satisfactory. The references are according to the journal's style and the tables are well organized. Nevertheless, some abbreviations throughout the text as well as in the tables need to be explicated. They are highlighted throughout the paper below. I suggest the paper to be published after these minor revisions.

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6877

Title: Clinical management of advanced gastric cancer: the role of new molecular drugs

Reviewer code: 02445518

Science editor: Su-Xin Gou

Date sent for review: 2013-10-30 14:56

Date reviewed: 2014-01-02 08:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The study "Clinical management of advanced gastric cancer: the role of new molecular drugs" from Dr. Ferdinando De Vita et al, Is an impressive, complete and accurate guide to new biological treatment for gastric cancer patients. Unfortunately the review, perfect for a text book, is too wide and not so useful for a journal without changes First of all it would be better that the new drugs were introduced in a more synthetic form and accompanied by algorithms. The Authors may indicate better what kind of drugs is now frequently used and which are instead generally used in phase 2 studies (as presented for studies in tables1-3). The simple presentation of several studies is a huge work that means a great knowledge of the subject, but for a journal review it would be of greater interest a sort of guide for.... how to select the best one drug for that patient. Moreover The EGJ cancer and upper gastric carcinoma, even if considered together in the last TNM staging, present great difference in prognosis and treatment ; they should be considered separately (for example proximal non diffuse GC is not related to reflux as cardia cancer). Diffuse gastric cancer is not always associated with a down regulation of CDH1 that it happens only in 1% of gastric cancer. This may be presented in a different way

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6877

Title: Clinical management of advanced gastric cancer: the role of new molecular drugs

Reviewer code: 01438559

Science editor: Su-Xin Gou

Date sent for review: 2013-10-30 14:56

Date reviewed: 2014-01-05 21:02

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is a nice review of the role of new molecular drugs for the treatment of advanced gastric cancer. It is well written and covers a broad area of molecular agents. It would be better to breakdown the introduction and conclusion to smaller paragraphs according to the subjects.